$4.31
-0.25 (-5.48%)
Open$4.52
Previous Close$4.56
Day High$4.52
Day Low$4.31
52W High$7.75
52W Low$1.31
Volume—
Avg Volume140.9K
Market Cap236.75M
P/E Ratio—
EPS$-2.55
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+178.7% upside
Current
$4.31
$4.31
Target
$12.01
$12.01
$8.14
$12.01 avg
$13.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 368.79M | 346.38M | 334.67M |
| Net Income | 5.96M | 4.54M | 4.70M |
| Profit Margin | 1.6% | 1.3% | 1.4% |
| EBITDA | 7.81M | 7.32M | 6.13M |
| Free Cash Flow | 4.41M | 4.25M | 6.96M |
| Rev Growth | +17.9% | -7.3% | +7.0% |
| Debt/Equity | 0.83 | 0.86 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |